We are live on
!
Find out more
LCG
Lisanti Capital Growth Portfolio holdings
AUM
$397M
1-Year Est. Return
178.66%
This Fund
S&P 500
This Quarter
Est. Return
+45.33%
1 Year Est. Return
+178.66%
3 Year Est. Return
+1,089.72%
5 Year Est. Return
+3,176.57%
10 Year Est. Return
+120,936.2%
AUM
$361M
AUM Growth
+$24.6M
(+7.3%)
Cap. Flow
-$42.3M
Cap. Flow
% of AUM
-11.73%
Top 10 Holdings %
Top 10 Hldgs %
20.84%
Holding
153
New
45
Increased
24
Reduced
31
Closed
47
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Credo Technology Group
CRDO
|
+$5.59M |
| 2 |
Tandem Diabetes Care
TNDM
|
+$5.03M |
| 3 |
Modine Manufacturing
MOD
|
+$4.87M |
| 4 |
Sterling Infrastructure
STRL
|
+$4.85M |
| 5 |
Celsius Holdings
CELH
|
+$4.47M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Palomar
PLMR
|
+$7.93M |
| 2 |
Casella Waste Systems
CWST
|
+$6.98M |
| 3 |
BrightSpring Health Services
BTSG
|
+$6.21M |
| 4 |
Krystal Biotech
KRYS
|
+$5.48M |
| 5 |
MASI
Masimo
MASI
|
+$5.08M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.37% |
| 2 | Industrials | 25.9% |
| 3 | Healthcare | 20.31% |
| 4 | Consumer Discretionary | 10.72% |
| 5 | Consumer Staples | 7.37% |
Similar funds
PIM
EH
TPWA
STT
VC
CF
IVLAV
MHC
Lisanti Capital Growth's Q2 2025 Portfolio in Review
As of Q2 2025, Lisanti Capital Growth held 153 positions worth $361M, up 7.3% from $336M the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Lisanti Capital Growth withdrew a net $42.3M in Q2 2025, closing 47 positions and reducing 31 holdings. Its most notable exit was Palomar, an estimated $7.93M position sold in full.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 20% a quarter earlier, followed by Industrials and Healthcare.
Against the trend, Lisanti Capital Growth opened a new position in Tandem Diabetes Care worth $4.73M.
- Lisanti Capital Growth's largest Q2 2025 buy was Tandem Diabetes Care: 253,840 shares worth $4.73M.
- Lisanti Capital Growth added most to Credo Technology Group in Q2 2025, an estimated $5.59M increase.
- Lisanti Capital Growth's biggest Q2 2025 reduction was Ligand Pharmaceuticals, cutting an estimated $4.48M.
- Lisanti Capital Growth fully exited Palomar in Q2 2025, selling an estimated $7.93M.
- Lisanti Capital Growth's ten largest holdings make up 21% of its $361M portfolio in Q2 2025.
- Lisanti Capital Growth opened 45 new positions and closed 47 in Q2 2025.
- Lisanti Capital Growth's portfolio value rose 7.3% quarter-over-quarter to $361M.
Based on Lisanti Capital Growth's 13F filing for Q2 2025, filed 7 Aug 2025.